Moderna (MRNA) Stock Climbs Nearly 4% Following Melanoma Trial Success and Vaccine Approval

Moderna: Massive Asymmetry About What The mRNA Is! (NASDAQ:MRNA)

Moderna's upside hinges on Intismeran’s ability to scale across multiple tumor types, not just melanoma. Learn why MRNA stock is a strong buy.

Moderna CEO warns China is investing heavily in mRNA as Beijing challenges US in biotechnology

Moderna’s stock is riding high after news of a personalized cancer treatment, but CEO Stéphane Bancel is warning about a bigger threat: China’s state-backed push to challenge the U.S. in biotechnology. In an interview on “Mornings with Maria” Monday, Bancel said that while Washington pulls back on mRNA funding, Beijing is pouring state money into […] The post Moderna CEO warns China is investing heavily in mRNA as Beijing challenges US in biotec…

Moderna (MRNA) Stock Climbs Nearly 4% Following Melanoma Trial Success and Vaccine Approval

Moderna (MRNA) stock climbed 3.6% on melanoma vaccine trial success and COVID approval, but analysts remain cautious with $80.53 average price target. The post Moderna (MRNA) Stock Climbs Nearly 4% Following Melanoma Trial Success and Vaccine Approval appeared first on Blockonomi.

Moderna Shares Gain 9.9% as Cancer-Vaccine Repricing Adds $5.6 Billion

CAMBRIDGE, Massachusetts, September 1, 2026, 16:20 EDT — Moderna closed at $154.27, up 9.93%, on 25.3 million shares.The gain added about $5.6 billion of implied equity value.Phase 3 intismeran results cleared two endpoints, but full efficacy data remain undisclosed.Management is due at investor conferences on September 14 and September 23. Moderna, Inc. (NASDAQ:MRNA) rose 9.93%…